MedPath

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients

Not Applicable
Completed
Conditions
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Registration Number
NCT00213798
Lead Sponsor
University Hospital, Strasbourg, France
Brief Summary

The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool. The aim of this study is to evaluate if plasma DNA can be used as a valuable non invasive test to monitor disease progression without assessing the tumor.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Presence of lung tumor to use fiberoscopy or surgical intervention for diagnosis.
  • No lung instability.
  • Individuals give all informed consent
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Service de Pneumologie, H么pital Lyautey

馃嚝馃嚪

Strasbourg, France

Service de Pneumologie, H么pital de Hautepierre

馃嚝馃嚪

Strasbourg, France

Service de Chirurgie Thoracique, H么pital Civil

馃嚝馃嚪

Strasbourg, France

Service de Pneumologie, H么pital Civil

馃嚝馃嚪

Strasbourg, France

漏 Copyright 2025. All Rights Reserved by MedPath